ArticleFrontiers in immunology2025
Analysis of m7G-related signatures in the tumor immune microenvironment and identification of clinical prognostic regulators in ovarian cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OV) is the most lethal gynecological malignancy in the world. At present, the effect of m7G modification-related genes on the development of ovarian cancer remains unclear. We performed consensus clustering of ovarian cancer samples based on the expression of 24 m7G modification-related genes, and obtained 2 subtypes. There were some differences in immune cell infiltration between the two subtypes. Furthermore, enrichment analysis showed that differential genes were mainly enriched in several pathways and biological processes, including positive translation regulation and TRAPP complex. Multivariate cox regression analysis confirmed two genes (DCP2 and NUDT16) related to prognosis for the construction of risk score prediction models. The risk map of survival status showed that the high-risk samples had a shorter survival time (p<0.05). Risk score was an independent prognostic factor for OV and correlated with immunotherapy response. We also performed network analysis for DCP2 and NUDT16. We further explored the effects of the genes on cellular function and prognosis. In conclusion, this study provided a new perspective for the development mechanism of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.